GlassScriptPhysician profile
Anthony M Daniels
NPI 1558398511
$1,297.14
in general payments reported to CMS, 2019-2025
14 companies · $99.06 in 2025
The $99.06 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.94 · 2020: $88.48 · 2021: $52.53 · 2022: $249 · 2023: $485 · 2024: $281 · 2025: $99.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $849 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $849.14 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $934.33 | 2019-2025 | Skyrizi, Rinvoq, Creon |
| Romark Laboratories, Lc | $66.03 | 2020 | |
| Pfizer INC. | $51.42 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $42.57 | 2024 | Dificid |
| Janssen Biotech, INC. | $36.32 | 2024-2025 | Stelara, Tremfya |
| Medtronic, INC. | $28.82 | 2022-2023 | Gi Genius |
| Allergan, INC. | $25.48 | 2019-2020 | |
| Celgene Corporation | $19.82 | 2022 | |
| Boston Scientific Corporation | $17.58 | 2025 | General - Hemostasis |
| Takeda Pharmaceuticals U.S.A., INC. | $16.32 | 2023 | Entyvio |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 | |
| Olympus America INC. | $15.65 | 2025 | Visiglide |
| Ferring Pharmaceuticals INC. | $15.35 | 2021 | |
| Braintree Laboratories, INC. | $11.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Daniels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.